Search

Your search keyword '"Tan, Daniel Shao Weng"' showing total 16 results
Start Over Author "Tan, Daniel Shao Weng" Publisher elsevier b.v.
16 results on '"Tan, Daniel Shao Weng"'

2. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC)

Author

Low, Joo-Leng, Lau, Dawn Pingxi, Zhang, Xiaoqian, Kwang, Xue-Lin, Rohatgi, Neha, Chan, Jane Vin, Chong, Fui-Teen, Wong, Stephen Qi Rong, Leong, Hui-Sun, Thangavelu, Matan Thangavelu, Rikka, Shivaji, Skanderup, Anders Martin Jacobsen, Tan, Daniel Shao Weng, Periyasamy, Giridharan, Koh, Judice Lie Yong, Iyer, N Gopalakrishna, and DasGupta, Ramanuj

Published
2021
Full Text
View/download PDF

7. Corrigendum to ‘A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC)’

Author

Low, Joo-Leng, Lau, Dawn Pingxi, Zhang, Xiaoqian, Kwang, Xue-Lin, Rohatgi, Neha, Chan, Jane Vin, Chong, Fui-Teen, Wong, Stephen Qi Rong, Leong, Hui-Sun, Thangavelu, Matan Thangavelu, Rikka, Shivaji, Skanderup, Anders Martin Jacobsen, Tan, Daniel Shao Weng, Periyasamy, Giridharan, Koh, Judice Lie Yong, Iyer, N Gopalakrishna, and DasGupta, Ramanuj

Published
2021
Full Text
View/download PDF

9. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.

Author

Felip, Enriqueta, de Braud, Filippo G., Maur, Michela, Loong, Herbert H., Shaw, Alice Tsang, Vansteenkiste, Johan F., John, Thomas, Liu, Geoffrey, Lolkema, Martijn P., Selvaggi, Giovanni, Giannone, Vanessa, Cazorla, Pilar, Baum, Jason, Balbin, O. Alejandro, Wang, Luojun (Victor), Lau, Yvonne Y., Scott, Jeffrey W., and Tan, Daniel Shao-Weng

Published
2020
Full Text
View/download PDF

13. Do elderly patients benefit from enrollment into Phase I Trials?

Author

Tai, Wai Meng, Lim, Cindy, Ahmad, Aziah, Ong, Whee Sze, Choo, Su Pin, Lim, Wan Teck, Tan, Eng Huat, Kanesvaran, Ravindran, and Tan, Daniel Shao Weng

Abstract

Background Despite the significant burden of cancer in the older population, their outcomes in the context of phase I studies have been poorly studied. While the Royal Marsden Hospital (RMH) prognostic score (albumin, lactate dehydrogenase [LDH], number of metastatic sites) is validated in this setting, its utility among the elderly is uncertain. Methods A total of 296 consecutive patients who were treated in 20 phase I trials from 2005 to 2012 in our unit were analysed. Clinical characteristics and outcomes between young (< 65, n = 202) and older patients (≥ 65, n = 94) were compared. Results The median age of the older patients was 69 years (65–84) and 71% were males. Although elderly patients had more co-morbidities and lower albumin levels at baseline, there was no significant difference in survival (8.8 months versus 9.9 months, p = 0.68) and clinical benefit rate (69% versus 56%, p = 0.07) compared to younger patients after median follow-up of 7.1 months (0.36–50.6 months). Age (p = 0.23) did not have any bearing on occurrence of grade 3/4 toxicities. Twenty-six percent of elderly patients experienced grade 3/4 toxicities. The prognostic factors for overall survival (OS) identified in multivariate analysis were prior lines of chemotherapy (0–2 versus ≥ 3), baseline sodium levels (≥ 135 versus < 135 mmol/L) and platelet levels (≤ 400 versus > 400 × 10 9 ). We developed a risk nomogram based on the factors prognostic of survival with concordance index of 0.65. The RMH model yielded a concordance index of 0.635. Conclusion Elderly patients enrolled into phase I clinical trials had similar survival outcomes and toxicity profiles compared to younger patients. Risk scoring models to aid patient selection need further clarification. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

15. PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4).

Author

Jr.De Castro, Gilberto, Tan, Daniel Shao-Weng, Crinò, Lucio, Wu, Yi Long, Paz-Ares, Luis, Wolf, Jürgen, Geater, Sarayut, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximilian, Cortot, Alexis, Tsai, Chun-Ming, Moro-Sibilot, Denis, García Campelo, Rosario, Branle, Fabrice, Sen, Paramita, Mcculloch, Tracey, and Soria, Jean-Charles

Published
2017
Full Text
View/download PDF

16. Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluation.

Author

Adine, Christabella, Fernando, Kanishka, Ho, Nicholas Ching Wei, Quah, Hong Sheng, Ho, Samantha Shu Wen, Wu, Kenny Zhuoran, Teng, Karen Wei Weng, Arcinas, Camille, Li, Ling, Ha, Kelly, Chew, Joey Wei Ling, Wang, Chenhui, Too, Nathaniel Sheng Hua, Yeong, Joe Poh Sheng, Tan, Daniel Shao Weng, Tan, Iain Bee Huat, Nagadia, Rahul, Chia, Claramae Shulyn, Macalinao, Dominique, and Bhuvaneswari, Hariraman

Subjects
*IMMUNE checkpoint inhibitors, *PROGRAMMED cell death 1 receptors, *HYDROGELS, *HEAD & neck cancer, *IMMUNE checkpoint proteins, *RNA sequencing
Abstract

Ex vivo patient-derived tumor slices (PDTS) are currently limited by short-term viability in culture. Here, we show how bioengineered hydrogels enable the identification of key matrix parameters that significantly enhance PDTS viability compared to conventional culture systems. As demonstrated using single-cell RNA sequencing and high-dimensional flow cytometry, hydrogel-embedded PDTS tightly preserved cancer, cancer-associated fibroblast, and various immune cell populations and subpopulations in the corresponding original tumor. Cell-cell communication networks within the tumor microenvironment, including immune checkpoint ligand-receptor interactions, were also maintained. Remarkably, our results from a co-clinical trial suggest hydrogel-embedded PDTS may predict sensitivity to immune checkpoint inhibitors (ICIs) in head and neck cancer patients. Further, we show how these longer term-cultured tumor explants uniquely enable the sampling and detection of temporal evolution in molecular readouts when treated with ICIs. By preserving the compositional heterogeneity and complexity of patient tumors, hydrogel-embedded PDTS provide a valuable tool to facilitate experiments targeting the tumor microenvironment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results